DNA & Clones

DNA was prepared from cell line WM3670. WM3670 is a metastatic human melanoma cell line with epithelial morphology. This cell line features the G469E mutation at codon 469 in the BRAF gene. The G469E mutation results in an amino acid substitution at position 469 in BRAF, from a glycine (G) to a glutamic acid (E). This mutation occurs within the highly conserved GXGXXG motif of the kinase domain. Most mutant BRAF proteins have increased kinase activity and are transforming in vitro. This cell line contains a G12D mutation at position 12 in the N-RAS gene. The G12D mutation results in an amino acid substitution at position 12 in N-RAS, from a glycine (G) to an aspartic acid (D).

DNA was prepared from cell line WM3670. WM3670 is a metastatic human melanoma cell line with epithelial morphology. This cell line features the G469E mutation at codon 469 in the BRAF gene. The G469E mutation results in an amino acid substitution at position 469 in BRAF, from a glycine (G) to a glutamic acid (E). This mutation occurs within the highly conserved GXGXXG motif of the kinase domain. Most mutant BRAF proteins have increased kinase activity and are transforming in vitro. This cell line contains a G12D mutation at position 12 in the N-RAS gene. The G12D mutation results in an amino acid substitution at position 12 in N-RAS, from a glycine (G) to an aspartic acid (D).

DNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3702. WM3702 is a metastatic human melanoma cell line that displays pigmented, thin elongated morphology in culture. This cell line was established from a right upper flank of back in a 58-year-old male with necrotic fungating melanoma. The subject displayed metastatic melanoma forming multiple subcutaneous nodules with overlying skin ulcerations. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3702 cells match with WM3758 and WM3682. These cells produce xenograft tumors when injected into immunocompromised mice.